CD4 and non-Hodgkin lymphoma: Indeed, in patients with non-Hodgkin’s lymphoma, naive and central memory CD4+ CAR-T cells from patients exhibit higher antitumor activity than effector memory CD4+ CAR-T cells when transferred to an animal model.